DSpace Repository

Occurrence of deranged liver enzymes among patients with rheumatoid arthritis treated with methotrexate

Show simple item record

dc.contributor.author Yadhury, S.
dc.contributor.author Kalki, P.
dc.contributor.author Kamshana, K.
dc.contributor.author Diluxcy, R.
dc.contributor.author Narani, A.
dc.date.accessioned 2026-11-17T03:14:55Z
dc.date.available 2026-11-17T03:14:55Z
dc.date.issued 2026
dc.identifier.uri http://repo.lib.jfn.ac.lk/ujrr/handle/123456789/13226
dc.description.abstract Background and objective Methotrexate is the anchor disease-modifying anti-rheumatic drug for rheumatoid arthritis, but elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) require clinical review and monitoring. This study determined the occurrence of deranged liver enzymes and associated factors among methotrexate-treated patients with rheumatoid arthritis. Methods A hospital-based descriptive cross-sectional study was conducted among 221 adults receiving methotrexate for at least six months at the Rheumatology Clinic, Teaching Hospital, Jaffna. Data were collected using an interviewer-administered questionnaire and a clinical-record extraction form. Deranged liver enzymes were defined as ALT or AST exceeding 1.5 times the upper limit of normal in any of the three most recent consecutive reports available at the time of data collection. Categorical and continuous variables were analyzed using the Chi-square/Fisher's exact test and Mann–Whitney U test, respectively, with p<0.05 indicating statistical significance. Results Deranged liver enzymes were identified in 20 participants (9.0%). Participants were predominantly female (85.5%); median age was 57 years (IQR 48–65), median weekly methotrexate dose was 10 mg (IQR 7.5–12.5), and median treatment duration was 5 years (IQR 2–7). Oral traditional medicine use was associated with deranged liver enzymes (21.7% among users versus 7.6% among non-users; p=0.042). Age, sex, alcohol use, concomitant anti-rheumatic therapy, methotrexate dose and treatment duration were not significantly associated. Conclusions Approximately one in eleven methotrexate-treated patients had deranged liver enzymes. Concomitant traditional medicine use was the only identified associated factor. Medication reconciliation and evaluation of alternative causes should accompany routine transaminase monitoring; causation cannot be inferred from this cross-sectional study. en_US
dc.language.iso en en_US
dc.publisher Faculty of Medicine University of Jaffna, Sri Lanka en_US
dc.subject Rheumatoid arthritis en_US
dc.subject Methotrexate en_US
dc.subject Aminotransferases en_US
dc.subject Traditional medicine en_US
dc.subject Cross-sectional study en_US
dc.title Occurrence of deranged liver enzymes among patients with rheumatoid arthritis treated with methotrexate en_US
dc.type Conference paper en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record